Role of fluoropyrimidine schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma

Journal of the National Cancer Institute

Volumn 88, Issue 7, 1996, Pages 430-436

  Cao, Shousong ^a   Frank, Cheryl ^a   Rustum, Youcef M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLOXURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; COLORECTAL CANCER; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; RAT; STOMATITIS;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLOXURIDINE; FLUOROURACIL; LEUCOVORIN; RATS; RATS, INBRED F344; TIME FACTORS;

EID: 0029929430     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.7.430     Document Type: Article

References (30)

1. Moertel CG. Chemotherapy of gastrointestinal cancer. N Engl J Med 1978;229:1049-52.
2. Davis HL. Chemotherapy of large bowel cancer. Cancer 1982;50:2638-46.
3. Lavin P, Mittelman A, Douglass H Jr, Engstrom P, Klaassen D. Survival and response to chemotherapy for advanced colorectal adenocarcinoma: an Eastern Cooperative Oncology Group report. Cancer 1980;46:1536-43.
4. Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987;107: 459-65.
5. Engstrom PF, MacIntyre JM, Mittelman A, Klaassen DJ. Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278). Am J Clin Oncol 1984;7:313-8.
6. Danenberg PV, Danenberg KD. Effect of 5, 10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanism. Biochemistry 1978;17:4018-24.
7. Evans RM, Laskin JD, Hakala MT. Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 1981;41:3288-95.
8. Rustum YM, Trave F, Zakrzewski SF, Petrelli N, Herrera L, Mittleman A, et al. Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. NCI Monogr 1987;5:165-70.
9. Keyomarsi K, Moran RG. Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells. J Biol Chem 1988;263:14402-9.
10. Keyomarsi K, Moran RG. Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res 1986;46:5229-35.
11. Zhang ZG, Rustum YM. Pharmacologic rationale for fluoropyrimidine-leucovorin combination: biochemical mechanisms. Semin Oncol 1992;19(2 Suppl 4):46-50.
12. Houghton JA, Maroda SJ Jr, Phillips JO, Houghton PJ. Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res 1981;41:144-9.
13. Houghton JA, Williams LG, Cheshire PJ, Wainer IW, Jadaud P, Houghton PJ. Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts. Cancer Res 1990;50:3940-6.
14. Zhang ZG, Rustum YM. Effect of diasteroisomers of 5-formyltetrahydrofolate on cellular growth, sensitivity to 5-fluoro-2′-deoxyuridine, and methylenetetrahydrofolate polyglutamate levels in HCT-8 cells. Cancer Res 1991; 51:3476-81.
15. Mini E, Moroson BA, Bertino JR. Cytotoxicity of floxuridine and 5-fluorouracil in human T-lymphoblast leukemia cells: enhancement by leucovorin. Cancer Treat Rep 1987;71:381-9.
16. Davis ST, Berger SH. Modulation of 5-fluoro-2′-deoxyuridine response by folinic acid in human colonic tumor cell lines: the role of thymidylate synthase. Mol Pharmacol 1989; 35:422-7.
17. Rustum YM. Toxicity and antitumor activity of 5-fluorouracil in combination with leucovorin. Role of dose schedule and route of administration of leucovorin. Cancer 1989;63(6 Suppl):1013-7.
18. Petrelli N, Herrera L, Rustum Y, Burke P, Creaven P, Stulc J, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987;5:1559-65.
19. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7: 1407-18.
20. Doroshow JH, Multhauf P, Leong L, Margolin K, Litchfield T, Akman S, et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 1990;8:491-501.
21. Di Costanzo F, Bartolucci R, Calabresi F, Sofra M, Marzola M, Belsanti V, et al. Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Ann Oncol 1992;3:371-6.
22. Piedbois P, Buyse M, Rustum Y, et al. Modualtion of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
23. Cao S, Zhang Z, Creaven PJ, et al. 5-Fluoro-2′-deoxyuridine: role of schedule in its therapeutic efficacy. In: Rustum YM, editor. Novel approaches to selective treatments of human solid tumors: laboratory and clinical correlation. New York: Plenun Press, 1993:1-8.
24. Zhang ZG, Harstrick A, Rustum YM. Mechanisms of resistance to fluoropyrimidines. Semin Oncol 1992;19:4-9.
25. Yin MB, Rustum YM. Comparative DNA strand breakage induced by FUra and FdUrd in human ileocecal adenocarcinoma (HCT-8) cells: relevance to cell growth inhibition. Cancer Commun 1991;3:45-51.
26. Cao S, Rustum YM, Spector T. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 1994;54:1507-10.
27. van Laar JA, Durrani FA, Rustum YM. Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2′-deoxyuridine ± N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26. Cancer Res 1993;53:1560-4.
28. Creaven PJ, Rustum YM, Petrelli NJ, Meropol NJ, Raghaven D, Rodriguez-Bigas M, et al. Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen. Cancer Chemother Pharmacol 1994;34:261-5.
29. Klubes P, Cerna I, Meldon MA. Effect of concurrent calcium leucovorin infusion on 5-fluorouracil cytotoxicity against murine L1210 leukemia. Cancer Chemother Pharmacol 1981;6:121-5.
30. Martin DS, Stolfi RL, Colofiore JR. Failure of high-dose leucovorin to improve therapy with the maximally tolerated dose of 5-fluorouracil: a murine study with clinical relevance? J Natl Cancer Inst 1988;80:496-501.